To The Moon

🟩📊 **REITs Win, Banks Struggle: JPMorgan's Latest Call 🏦** Join Iggy at the Investing Iguana as we dive into JPMorgan’s latest financial analysis on why REITs are thriving while banks face challenges in today’s lower interest rate environment. Packed with insights, this video sheds light on how Singapore banks are managing net interest margin (NIM) pressures and adapting through fee income growth. Meanwhile, REITs are emerging as winners, benefiting from lower borrowing costs and strong local market conditions. 📈 **Key Takeaways for Investors:** - 🏦 **Banks’ Struggles:** Learn why Singapore banks like DBS, OCBC, and UOB are feeling the squeeze amidst falling interest rates but still holding steady with strong fee income streams. - 🏢 **REITs’ Resilience:** Discover why REITs like Capitaland

$Advanced Micro Devices(AMD)$ has ignited excitement in the semiconductor sector with a nearly 9% surge in its stock price on June 16, 2025, following optimistic analyst commentary. Piper Sandler raised their price target from $125 to $140, citing expectations of a "snapback" in AMD’s graphics processing unit (GPU) business by the fourth quarter, as the company moves past $800 million in charges related to U.S. export restrictions to China. This rally, bolstered by AMD’s unveiling of the Helios full-server rack, raises critical questions: Is this rally sustainable, can AMD breach the $140 mark, and which chip stocks hold the most upside potential in this AI-driven market? This article explores AMD’s momentum, its competitive landscape, and the broa

How I Secured My Final Dividend from VST and Recovered It with a Smart Options Move 💼📉 As the expiry of my covered call nears and my 100 shares of Vistra Energy (VST) are likely to be called away at the $135 strike on 20 June 2025, I took one last opportunity to capture the dividend while also executing a calculated options strategy to recover its value. The dividend payout of $0.225 per share on 18 June translates into a total of $22.50 for my lot of 100 shares. Knowing that once my shares are called away I would no longer be eligible for future dividends, I decided to make one final intelligent play. 📅 Capturing the Dividend While It Lasts I held on to my 100 shares of VST long enough to qualify for the $0.225 dividend. With my average purchase price at $155 and the current market price

$Sarepta Therapeutics(SRPT)$ Sarepta Therapeutics (NASDAQ: SRPT), a biotechnology company at the forefront of genetic medicine with a special focus on Duchenne muscular dystrophy (DMD), delivered its Q1 2025 earnings report, offering investors a nuanced blend of optimism and caution. While revenue growth remains solid and early returns from its recently launched gene therapy drug Elevidys are encouraging, Sarepta is still navigating the challenges of scaling its commercial operations, securing broad regulatory approvals, and achieving sustainable profitability. Sarepta Therapeutics, a key player in the gene therapy space focused on treating Duchenne muscular dystrophy (DMD), saw its shares plunge by over 46% after the company disclosed a second pa